

# FluCov Influenza Activity Report #10

29 January 2024


## Take home: continued elevated influenza activity in the Northern Hemisphere

- North America and Europe:** Influenza activity in is decreasing, but remains elevated with moderate to high activity in many U.S states. In Europe, a mixed activity pattern was observed, with medium activity in most countries (Denmark, France, Germany, Italy) and low activity in the UK. Spain, like most EU/EEA countries, reported widespread influenza activity.
- Asia:** Influenza overall positivity rate decreased in China, but remained over 30% in week 03/2024. medium activity is now reported in both Northern and Southern China.
- Circulating virus:** While A/H3 and B/Victoria have predominated globally and in China, A/H1N1pdm09 has dominated circulation in most of the Northern Hemisphere. Presently, there are no documented cases of B-Yamagata
- Vaccine match:** Early indicators in the US suggest good vaccine match. France reports good match with A/H1N1pdm09, but mismatch in some percentage of A/H3 viruses. The mismatch viruses seem to be in the same genetic clade as the strain recommended for 2024 SH vaccine.
- Influenza Viruses of Pandemic Potential:** On Jan 26 & 28 Cambodia announced two new severe, hospitalized H5N1 cases in a 3-year-old from Prey Veng province and a 68-year-old from Siem Reap; specific clade of the circulating viruses is expected be available in due course. (Promed).
- COVID hospitalizations:** Are decreasing in Italy and the US, after a peak around the end of 2023. For England, the last update was on 7 December 2023, hospitalizations were increasing at the time, after a period of decrease.

## Positive Influenza tests (%)


**Note:** France's positivity rate graph was last updated week 51/2023, for Germany, UK, Denmark and Italy, the last update was week 2/2024.

— Season 2023/2024   
 — Season 2022/2023   
 — Season 2021/2022   
 — Average of pre-COVID-19 seasons (2014/2015 to 2018/2019) [Min; Max]



## Weekly hospital SARS-CoV-2 hospital admissions

(US, Italy, England; admissions/million)



Displayed data is the most recent reported; it is possible that there may be a delay in reporting. Most recent estimates subject to change (e.g. may decline) due to ongoing testing of specimen. Data only available for three countries at the moment.

---

### Data sources & details

**US:** FluView (Clinical Laboratories)  
**DK:** WHO FluNET (non-sentinel)  
**EU text:** ERVISS  
**All others:** WHO FluNet (sentinel)  
**COVID:** Our World in Data.

### A Nivel publication

FluCov team: Bronke Boudewijns, Susanne Heemskerk, Marco Del Riccio, Saverio Caini, John Paget.

[FluCov Influenza Activity Report #10: 29 January 2024](#). Netherlands, Utrecht: Nivel, 2024

### Websites for more information

Project Website: <https://www.nivel.nl/en/flucoV>

FluCoV Dashboard: <https://www.nivel.nl/en/flucoV-dashboard>

### Funding

The Nivel FluCov project is funded by Sanofi

---